2022-7-1 Executive Team Meeting notes

Date

01 Jul 2022

Attendees

Committee Member	Present	Absent
Kuffel, Gina (NIH/NCI) [C]	X	
Unknown User (leblancak)	X	
Otridge, John (NIH/NCI) [C]	X	
Kim, Erika (NIH/NCI) [E]	X	
Sommers, Connie (NIH/NCI) [E]		
Debbie Knapp	X	
Toby Hecht	X	
Unknown User (parchmentr)	X	

Goals

- Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items

- [x] Kuffel, Gina (NIH/NCI) [C] to send email to Debbie about importance of review article.

Agenda

Item	Who	Talking Points

DGAB Updates	Kuffel, Gina (NIH/NCI) [C]	• 33 TB of data are now available in ICDC (five-fold increase since January)
		• TCL01 study has been loaded into our Dev tier
		• 1st PRECINCT study has been approved by the DGAB & SAC
		• PRECINCT has used templates available from the ICDC Data Model Explorer (DME) for the fist ever load of a study via submitter-generated loading files
		  ◦ Initial version of data is available in Dev tier
		  ◦ Waiting on significant data updates from study owners before proceeding with a reload of the study in updated and somewhat expanded form
		• Will has volunteered his time to create a scientific use case from ICDC data

BPSC Updates	Kuffel, Gina (NIH/NCI) [C]	• 2022 BPSC Review Article
		  ◦ Outline completed
		  ◦ Preliminary section assignments have been made
		  ◦ Communicate deadline of August 1, 2022
		  ◦ Communicate that future funding hinges upon this publication

June Steering Committee Updates	Unknown User (parchmentr)	• Minutes to be posted • Next meeting is ?

ICDC Site Updates	Kuffel, Gina (NIH/NCI) [C]	• Next software release for ICDC targets July 7th
		  ◦ ICDC Static News Page
		  ◦ Data Availability Landscape (DAL)
		  ◦ Gene annotations for JBrowse

ICDC Next Phase Planning	Unknown User (hechtt)	• Request for Information (RFI) • 2 focus groups met ◦ Ideas from the ICDC brainstorming sessions final.docx

Minutes (Not Verbatim)

Toby- Understanding of RFI is to go out ask for people doing comparative oncology across humans and dogs research to come up with questions or case studies or hypotheses that can leverage data in the ICDC to answer these question to expose gaps of data to inform the type of data we would like to source in the future.

DK- To identify key questions and if ICDC can help to answer these questions.

Toby- Who will be the PoC? I will do an outline of this and then circulate to this to the Executive Team.

JO - Executive TEam and then polish for broader dissemination to the Steering Committee.

Toby- We can send out to the Cancer Centers

AL - We can encourage all to share broadly

Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

    1. Search for conserved mutations between canine and human tumors

    2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

    5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

    6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

    7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

    8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Previous Meeting Minutes (Not Verbatim)

Toby - Can canine bladder cancer be a good model for invasive human bladder cancer? Maybe running differential expression in dogs at various stages vs. human data at different stages of disease obtained from the GDC and then comparing expression patterns and gene signatures. Real focus is comparative genomics.

Ralph - Possibly raise as a discussion point to the SC. Does this cancer in both species survive therapy to resist disease using same pathways? Is there biological convergence?

Toby - Look at dogs in ICDC and see what the genes are in dogs that are more resistant to glioma vs. dogs that are not and see if those up or down regulated genes have human homologs.

Toby - Real data in ICDC can now be used to answer real biological questions.

Ralph - Will put use case into SC meeting agenda.

Action item

- [ ] Toby to work on outline for RFI